JB

Jasper Bos

General Partner at Forbion

Amsterdam, North Holland

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Biotechnology
Drug Discovery
Technology Transfer
Lifesciences
Pharmaceutical Industry
Health Economics
Oncology
Clinical Trials
Molecular Biology
Drug Development
Clinical Development
R&D
Regulatory Affairs
Biopharmaceuticals
Vaccines
GCP
Market Access
Neuroscience
Competitive Intelligence
Commercialization

Education

Investments

Engrail Therapeutics

Series B

Total Funding: $220M

Precirix

Series B

Total Funding: $130M

Anaveon

Series B

Total Funding: $160M

Inthera Bioscience

Seed

Total Funding: $20M

Prexton Therapeutics

Series A

Total Funding: $41M

ARTSaVIT

Series A

Total Funding: $6M

Metabomed

Series A

Total Funding: $18M

Work Experience

enGene

2023

  • Board Member

    2023

ANAVEON AG

2022

  • Board Member

    2022

Forbion

2021

  • General Partner

    2021

  • Forbion European Acquisition Corporation (NASDAQ: FRBN) Chief Executive Officer

    2021 - 2023

M Ventures

2016 - 2021

  • Senior Vice President & Managing Director

    2019 - 2021

  • Vice President, Head of Healthcare Fund M Ventures

    2016 - 2019

Metabomed Ltd.

2016 - 2021

  • Member of the Board of Directors

    2016 - 2021

Galecto, Inc.

2012 - 2019

  • Member of the Board of Directors

    2012 - 2019

Calypso biotech SA

2013 - 2019

  • Chairman Of The Board Of Directors

    2013 - 2019

Prexton Therapeutics SA

2012 - 2018

  • Board Member

    2012 - 2018

Neviah Genomics

2012 - 2016

  • Board Member

    2012 - 2016

Merck Serono

2009 - 2016

  • Senior Director MS Ventures

    2014 - 2016

  • Director Merck Serono Ventures

    2011 - 2014

  • Associate Director Merck Serono Ventures

    2009 - 2011